About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Zfp36tm4.1Pjb
targeted mutation 4.1, Perry J Blackshear
MGI:5441582
Summary 1 genotype
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Zfp36tm4.1Pjb/Zfp36tm4.1Pjb
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N MGI:5441587


Genotype
MGI:5441587
cn1
Allelic
Composition
Zfp36tm4.1Pjb/Zfp36tm4.1Pjb
Lyz2tm1(cre)Ifo/Lyz2+
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lyz2tm1(cre)Ifo mutation (14 available); any Lyz2 mutation (40 available)
Zfp36tm4.1Pjb mutation (1 available); any Zfp36 mutation (19 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
N
• mice do not become sick enough to require euthanasia unlike Zfp36tm1.2Xen homozygotes

immune system
• in some mice
• in LPS-treated mice
• modest at 3 to 4 months in female mice
• 110 fold in LPS-treated mice
• in some mice
• widespread inflammatory cell infiltrates in liver, kidney, and lung in LPS-treated mice
• LPS-treated mice exhibit dramatic signs of endotoxemia (lethargy, tachypnea, piloerection and decreased body temperature); elevated TNF serum levels; enlarged spleens and dilated small intestines, with widespread inflammatory cell infiltrates in liver, kidney, and lung; scattered foci of hepatic necrosis, glomerular hypercellularity, and pulmonary alveolitis; and 5-fold increase in serum alanine aminotransferase, a 2.2-fold increase in blood urea nitrogen, and a 3-fold increase in lactate dehydrogenase compared with control mice
• mild interphalangeal arthritis and inflammation in 1 of 4 mice
• in LPS-treated mice

muscle
• mild inflammation and fibrosis in 3 of 4 mice at 8 months

homeostasis/metabolism
• 2.2-fold in LPS-treated mice
• 110 fold in LPS-treated mice
• dramatic in LPS-treated mice

behavior/neurological
• dramatic in LPS-treated mice
• dramatic in LPS-treated mice

respiratory system
• in LPS-treated mice
• dramatic in LPS-treated mice

cardiovascular system
• mild inflammation and fibrosis in 3 of 4 mice at 8 months

growth/size/body
• at 6.5 months in female mice
• at 9 months in male mice
• in some mice
• in LPS-treated mice
• modest at 3 to 4 months in female mice

digestive/alimentary system
• dilated in LPS-treated mice

liver/biliary system
• scattered foci of hepatic necrosis in LPS-treated mice

hematopoietic system
• in some mice
• in LPS-treated mice
• modest at 3 to 4 months in female mice

renal/urinary system
• glomerular hypercellularity in LPS-treated mice

skeleton
• mild interphalangeal arthritis and inflammation in 1 of 4 mice





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/12/2024
MGI 6.24
The Jackson Laboratory